

**FORM 51-102F3**  
**MATERIAL CHANGE REPORT**

1. **Name and Address of Company**

**Relay Medical Corp. (formerly, ChroMedX Corp.)** (the “Company”)  
401 Bay Street, 16<sup>th</sup> Floor  
Toronto, Ontario M5H 2Y4

2. **Date of Material Changes**

May 17, 2019

3. **News Release**

Press releases disclosing the material changes were released on May 17, 2019, through the facilities of Newsfile Corp.

4. **Summary of Material Changes**

The Company announces the closing of a private placement financing (the “**Offering**”) for gross proceeds of \$1,532,500 through the issuance of 7,662,500 units (each, a “**Unit**”) at a price of \$0.20 per Unit. Each Unit is comprised of: (1) one common share in the capital of the Company (each, a “**Common Share**”) and (ii) one Common Share purchase warrant (each, a “**Warrant**”). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of \$0.30 on or before November 17, 2020.

5. **Full Description of Material Change**

A full description of the material change is described in the Company’s press release dated May 17, 2019, which is attached as Schedule “A” hereto.

The following supplementary information is provided in accordance with Section 5.2 of Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions* (“**MI 61-101**”).

**(a) a description of the transaction and its material terms:**

Certain officers, directors and/or employees of the Company (the “**Related Parties**”), subscribed for an aggregate of 517,500 Units issued pursuant to the Offering.

**(b) the purpose and business reasons for the transaction:**

The Company plans to use the net proceeds of the Offering for working capital and general corporate purposes.

**(c) the anticipated effect of the transaction on the issuer’s business and affairs:**

The Company plans to use the net proceeds of the Offering for working capital and general corporate purposes.

**(d) a description of:**

**(i) the interest in the transaction of every interested party and of the related parties and associated entities of the interested parties:**

The Related Parties' participation in the Offering consisted of subscriptions for an aggregate of 517,500 Units as follows:

<b>Name</b>	<b>Position</b>	<b>Number of Units</b>	<b>Aggregate Price</b>
Lahav Gil	Chief Executive Officer and Director	175,000	\$35,000
Igal Roytblat	Chief Technology Officer	70,000	\$14,000
Kailasanathan Rajakuhendran	EVP Corporate Finance	225,000	\$45,000
Laura Karik	Employee	47,500	\$9,500

**(ii) the anticipated effect of the transaction on the percentage of securities of the issuer, or of an affiliated entity of the issuer, beneficially owned or controlled by each person or company referred to in subparagraph (i) for which there would be a material change in that percentage:**

Prior to the completion of the Offering, Mr. Gil held, directly or indirectly 5,546,828 Common Shares. Upon closing of the Offering, Mr. Gil holds an aggregate of 5,721,828 Common Shares, representing approximately 4.73% of the issued and outstanding Common Shares on an undiluted basis, and 175,000 Warrants. In the event that Mr. Gil exercises his Warrants, he would hold an aggregate of 5,546,828 Common Shares, or approximately 4.87% of the issued and outstanding Common Shares of the Company, on a partially diluted basis.

Prior to the completion of the Offering, Mr. Roytblat held, directly or indirectly, 343,263 Common Shares. Upon closing of the Offering, Mr. Roytblat holds, directly and indirectly, an aggregate of 413,263 Common Shares, representing approximately 0.34% of the issued and outstanding Common Shares on an undiluted basis, and 70,000 Warrants. In the event that Mr. Roytblat exercises his Warrants, he would hold an aggregate of 483,263 Common Shares, or approximately 0.39% of the issued and outstanding Common Shares of the Company, on a partially diluted basis.

Prior to the completion of the Offering, Mr. Rajakuhendran held, directly or indirectly, 227,417 Common Shares. Upon closing of the Offering, Mr. Rajakuhendran holds, directly and indirectly, an aggregate of 452,417 Common Shares, representing approximately 0.37% of the issued and outstanding Common Shares on an undiluted basis, and 225,000 Warrants. In the event that Mr. Rajakuhendran exercises his Warrants, he would hold an aggregate of 677,417 Common Shares, or approximately 0.55% of the issued and outstanding Common Shares of the Company, on a partially diluted basis.

Prior to the completion of the Offering, Ms. Karik did not hold any securities, directly or indirectly. Upon closing of the Offering, Ms. Karik holds, directly and indirectly, an aggregate of 47,500 Common Shares, representing approximately 0.04% of the issued and outstanding Common Shares on an undiluted basis, and

47,500 Warrants. In the event that Ms. Karik exercises her Warrants, she would hold an aggregate of 95,000 Common Shares, or approximately 0.7% of the issued and outstanding Common Shares of the Company, on a partially diluted basis.

- (e) **unless this information will be included in another disclosure document for the transaction, a discussion of the review and approval process adopted by the board of directors and the special committee, if any, of the issuer for the transaction, including a discussion of any materially contrary view or abstention by a director and any material disagreement between the board and the special committee:**

A resolution of the board of directors was passed on May 15, 2019 approving the Offering, with the Related Parties, as applicable, abstaining from voting in respect of their respective participation in the offering. No special committee was established in connection with the transaction, and no materially contrary view or abstention was expressed or made by any director.

- (f) **A summary in accordance with section 6.5 of MI 61-101, of the formal valuation, if any, obtained for the transaction, unless the formal valuation is included in its entirety in the material change report or will be included in its entirety in another disclosure document for the transaction:**

Not applicable.

- (g) **disclosure, in accordance with section 6.8 of MI 61-101, of every prior valuation in respect of the issuer that relates to the subject matter of or is otherwise relevant to the transaction:**

- (i) **that has been made in the 24 months before the date of the material change report:**

Not applicable.

- (ii) **the existence of which is known, after reasonable enquiry, to the issuer or to any director or officer of the issuer:**

Not applicable.

- (h) **the general nature and material terms of any agreement entered into by the issuer, or a related party of the issuer, with an interested party or a joint actor with an interested party, in connection with the transaction:**

Other than the subscription agreements to purchase the Units pursuant to the Offering, the Company did not enter into any agreement with an interested party or a joint actor with an interested party in connection with the Offering. To the Company's knowledge, no related party to the Company entered into any agreement with an interested party or a joint actor with an interested party, in connection with the Offering.

- (i) **disclosure of the formal valuation and minority approval exemptions, if any, on which the issuer is relying under sections 5.5 and 5.7 of MI 61-101 respectively, and the facts supporting reliance on the exemptions:**

The participation in the Offering by the Related Parties is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of securities being issued to the Related Parties nor the consideration being paid by the Related Parties exceeded 25% of the Company's market capitalization.

6. **Reliance on subsection 7.1(2) of National Instrument 51-102**

The report is not being filed on a confidential basis.

7. **Omitted Information**

No significant facts have been omitted from this Material Change Report.

8. **Executive Officer.**

For further information, contact W. Clark Kent, President of the Company at (647) 872-9982 ext 2.

9. **Date of Report.**

This report is dated at Toronto, this 27<sup>th</sup> day of May, 2019.



**Contact:**

**Office: 647-872-9982**

**Toll-free/Fax: 1-844-247-6633**

Email: [info@relaymedical.com](mailto:info@relaymedical.com)

Suite 1600-401 Bay St.

Toronto, Ontario M5H 2Y4

---

### **Relay Medical Announces Closing of Private Placement for Proceeds of Over \$1.5M**

May 17, 2019 – Relay Medical Corp. ("**Relay**" or the "**Company**") (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), a developer of MedTech innovation, is pleased to announce the closing of a private placement financing (the "**Offering**") for gross proceeds of \$1,532,500 through the issuance of 7,662,500 Units (each, a "**Unit**") at a price of \$0.20 per unit.

Each Unit is comprised of: (i) one common share in the capital of the Company (each a "**Common Share**"); (ii) one Common Share purchase warrant (each, a "**Warrant**"). Each whole Warrant entitles the holder to purchase one additional Common Share at an exercise price of \$0.30 on or before November 17, 2020.

Gross proceeds raised from the Offering will be used for working capital and general corporate purposes. The securities issued upon closing of the Offering are subject to a hold period until September 18, 2019, pursuant to applicable securities laws.

Certain eligible persons (the "**Finders**") were paid a cash commission equal to 8% of the proceeds raised from subscribers introduced to the Company by such Finder and also issued an aggregate of 93,200 finder warrants (the "**Finder Warrants**") to Finders, each Finder Warrant entitling the holder to acquire one Unit at a price of \$0.20 for a period of eighteen (18) months from the date of issuance.

Certain insiders of the Company participated in the First Tranche of the Offering, purchasing an aggregate of 517,500 Units. The participation of such insiders constitutes a "related party transaction" as defined under Multilateral Instrument 61-101 - *Protection of Minority Security Holders in Special Transactions*. The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as the fair market value of the participation in the Offering by insiders does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101. The Company did not file a material change report in respect of the related party transaction at least 21 days before the closing of the Offering, which the Company deems reasonable in the circumstances so as to be able to avail itself of the proceeds of the Offering in an expeditious manner.

#### **About Relay Medical Corp.**

Relay Medical is an evolving "Integrated MedTech Accelerator" headquartered in Toronto, Canada, acquiring early-stage technologies and inventions, advancing and preparing them for pre-commercial acquisitions in the HealthTech marketplace. By integrating the funding, development and exit process into one organization led and managed by one expert team, Relay Medical is building the capacity to accelerate and transact technologies with high efficiency and grow into a leading engine for MedTech innovation in the global HealthTech marketplace.

Website: [www.relaymedical.com](http://www.relaymedical.com)

**Contact:**

W. Clark Kent  
President  
Relay Medical Corp.  
Office. 647-872-9982 ext. 2  
TF. 1-844-247-6633 ext. 2  
[investor.relations@relaymedical.com](mailto:investor.relations@relaymedical.com)

Bernhard Langer  
EU Investor Relations  
Office. +49 (0) 177 774 2314  
Email: [blanger@relaymedical.com](mailto:blanger@relaymedical.com)

**Forward-looking Information Cautionary Statement**

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the commercialization plans for UXD described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at [www.sedar.com](http://www.sedar.com)